ORIGINAL ARTICLE   

Minerva Cardioangiologica 2018 February;66(1):16-25

DOI: 10.23736/S0026-4725.17.04438-3

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Evaluation of On-Clopidogrel platelet reactivity overtime, SYNTAX SCORE, genetic polymorphisms and their relationship to one year clinical outcomes in STEMI patients undergoing PCI

Harsha V. ERATHI ¹, Rajasekhar DURGAPRASAD ¹ ✉, Vanjakshamma VELAM ¹, Sarma PVGK ², Madhavi Rodda ¹, Kapil C ¹, Sreedhar N. KANAVATH ¹

¹ Department of Cardiology, Sri Venkateswara Institute of Medical Sciences, Tirupati, Andhra Pradesh, India; ² Department of Biotechnology, Sri Venkateswara Institute of Medical Sciences, Tirupati, Andhra Pradesh, India

BACKGROUND: The aim of this paper was to investigate the variability of On-clopidogrel platelet reactivity overtime, the association between HTPR, gene polymorphism and Syntax Score (SS) for risk prediction of MACE in patients with ST-Elevation Myocardial Infarction (STEMI) undergoing percutaneous coronary intervention (PCI). Platelet function testing may be used to optimize antiplatelet therapy in high-risk patients, but identification of this subset of patients remains a challenge. High on-treatment platelet reactivity (HTPR) has emerged as a risk factor for major adverse cardiovascular events (MACE). Genetic polymorphisms play key role in clopidogrel hypo-responsiveness.
METHODS: This prospective, observational study includes 151 consecutive STEMI patients who underwent PCI and treated with clopidogrel. Platelet Activity Index (PAI) was measured at two different time points post-PCI. Patients were stratified by the presence of HTPR (PAI≥5) and by upper SS (SS≥15). Allele-specific polymerase chain reaction for identifying CYP2C19*2, CYP3A5*3, PON1, P2Y12 gene polymorphisms was done. The end point at one year follow up was MACE.
RESULTS: There was a significant increase in mean platelet reactivity and the total number of non-responders over a period of three months (9.9% vs. 23.8% P=0.05). Patients with SS≥15 in the presence of HTPR during follow-up had highest rates of MACE, especially among diabetics compared to non-diabetics (P=0.024). The prevalence of CYP2C19*2 polymorphism was 49%%, was associated with HTPR during follow-up but unassociated with MACE.
CONCLUSIONS: In STEMI patients undergoing PCI, the presence of SS≥15, HTPR during follow-up were associated with high MACE rates especially among diabetics. Hence, such high-risk groups shall require sequential testing for HTPR and optimize therapy accordingly.

KEY WORDS: Platelet aggregation - Clopidogrel - Polymorphism, genetic